Table 2

Major trials of lipid lowering treatment in diabetes

See box for explanation of trial acronyms.
Major trials containing large numbers of subjects with diabetes for secondary prevention

  • 4S: simvastatin, 4444 subjects, 202 with diabetes

  • CARE: pravastatin, 4159 subjects, 586 with diabetes

  • LIPID: pravastatin, 9014 subjects, 782 with diabetes

  • HPS: simvastatin, 20536 subjects, 13386 subjects with prior myocardial infarction or other coronary heart disease, 1981 with diabetes

  • VA-Hit: gemfibrozil, 2531 subjects, 627 with diabetes

Major trial containing large numbers of subjects with diabetes for primary prevention

  • HPS: simvastatin, 7150 subjects with no prior coronary heart disease, 3982 subjects with diabetes